$2.21
+0.16 (+7.80%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALEC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 4 with posted results
Held by 11 tracked-famous managers (Balyasny Asset Management L.P., D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, +6 more) · FINRA short interest 12.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 4 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)NCT04374136Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SBRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The trial did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB) | Drug: AL001, Placebo, Open label - AL001 | Frontotemporal Dementia | 119 | 2025-09-01actual | 2026-01-21 |
| Continuation Study for LatozinemabNCT06111014Number of participants receiving latozinemabOpen-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's | Drug: Latozinemab | Neurodegenerative Diseases | 17 | 2025-09-01actual | 2026-01-21 |
| A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseNCT05744401results2026-02-25Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs).Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. | Drug: AL002 | Alzheimer's Disease | 197 | 2025-01-31actual | 2026-02-25 |
| A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874results2025-10-29Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AL002, Placebo | Alzheimer Disease | 356 | 2024-08-19actual | 2025-10-29 |
| A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)NCT03987295results2025-08-22Severity of TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AL001 | Frontotemporal Dementia | 33 | 2024-06-05actual | 2025-12-05 |
| A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALSNCT05053035results2025-06-18Evaluation of Safety and Tolerability of AL001 Measured by Number of Subjects With Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The Sponsor is considering a subsequent study in ALS, potentially with different inclusion/exclusion criteria. | Drug: AL001, Placebo | Amyotrophic Lateral Sclerosis | 5 | 2022-10-28actual | 2025-06-18 |
| A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101NCT04111666Evaluation of safety and tolerability of AL101 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: AL101 · Other: Placebo | Healthy | 88 | 2022-06-09actual | 2022-08-10 |
| First in Human Study for Safety and Tolerability of AL003.NCT03822208Evaluation of safety and tolerability of AL003 measured by number of subjects with adverse events and dose limiting adverse events (DLAE)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Biological: AL003 · Other: Saline Solution | Healthy, Alzheimer Disease | 54 | 2021-05-06actual | 2021-09-17 |
| A Phase I Study for Safety and Tolerability of AL002.NCT03635047Evaluation of safety and tolerability of AL002 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Biological: AL002 · Other: Saline Solution | Healthy, Alzheimer Disease | 69 | 2020-08-03actual | 2020-12-09 |
| A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) MutationNCT03636204Evaluation of safety and tolerability of AL001 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: AL001 · Other: Placebo | Healthy, Frontotemporal Dementia | 64 | 2019-12-31actual | 2020-07-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19